Thanks to the expansion of the PEARLITOL® mannitol range, the Roquette Group meets the quality and precision requirements of the pharmaceutical sector. These innovations make it possible to expand the areas of application, particularly to controlled-release tablets, and to facilitate the implementation of active ingredients by its customers.
The extension of the PEARLITOL® range with PEARLITOL® SD Mannitol in 2022 supports the creation of advanced dosage forms for tablets, even in the case of difficult active ingredient use. This innovation ensures that the stability of active ingredients sensitive to reducing sugars is not affected. Specifically developed with a narrow and controlled distribution of particle size, PEARLITOL® 150 SD offers good processability and reliable dosing in each tablet.
In addition to offering distinct advantages such as consistent quality, superior functionality, and high stability, Roquette’s PEARLITOL® SD range brings excellent organoleptic properties and allows for the reduction of costs related to direct compression formulations. It also relies on Roquette’s extensive expertise and technical know-how in solid oral formulations, as well as 40 years of experience in supplying excipients and raw materials of plant origin at the forefront of the industry.
At the CPHi trade show dedicated to pharmaceutical industry professionals in November 2022, Roquette revealed two excipients specially developed to meet the unique challenges of drug formulation in the pharmaceutical space. PEARLITOL® CR-H Mannitol and PEARLITOL® 200 GT Mannitol expand the range, helping manufacturers optimize direct compression processes and expand into new areas of application, such as controlled-release tablets and mini-tablets.
This range developed by the group’s teams is also part of Roquette’s Quality by Design pledge, an innovative commitment to ensuring the quality of excipient design developed by Roquette, with specific documentation for use to support qualification and registration processes. This proof reinforces the group’s commitments to responsible and sustainable innovation, to the benefit of its customers and patients.
If you liked this article, support us !
